Lisata Therapeutics (LSTA) Competitors $2.52 +0.01 (+0.40%) Closing price 02/12/2025 04:00 PM EasternExtended Trading$2.57 +0.05 (+1.98%) As of 02/12/2025 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends LSTA vs. ALTS, IGMS, DBVT, ADAG, AVTX, TNYA, PWUP, ALGS, VTGN, and ZIVOShould you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include Janone (ALTS), IGM Biosciences (IGMS), DBV Technologies (DBVT), Adagene (ADAG), Avalo Therapeutics (AVTX), Tenaya Therapeutics (TNYA), PowerUp Acquisition (PWUP), Aligos Therapeutics (ALGS), Vistagen Therapeutics (VTGN), and ZIVO Bioscience (ZIVO). These companies are all part of the "pharmaceutical products" industry. Lisata Therapeutics vs. Janone IGM Biosciences DBV Technologies Adagene Avalo Therapeutics Tenaya Therapeutics PowerUp Acquisition Aligos Therapeutics Vistagen Therapeutics ZIVO Bioscience Lisata Therapeutics (NASDAQ:LSTA) and Janone (NASDAQ:ALTS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership. Is LSTA or ALTS more profitable? Lisata Therapeutics' return on equity of -51.19% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets Lisata TherapeuticsN/A -51.19% -45.16% Janone N/A -2,940.01%-39.81% Does the MarketBeat Community favor LSTA or ALTS? Lisata Therapeutics received 14 more outperform votes than Janone when rated by MarketBeat users. CompanyUnderperformOutperformLisata TherapeuticsOutperform Votes1493.33% Underperform Votes16.67%JanoneN/AN/A Which has better earnings & valuation, LSTA or ALTS? Janone has higher revenue and earnings than Lisata Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLisata TherapeuticsN/AN/A-$20.84M-$2.51-1.00Janone$39.61M2.17-$7.81MN/AN/A Which has more volatility and risk, LSTA or ALTS? Lisata Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Janone has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Does the media refer more to LSTA or ALTS? In the previous week, Lisata Therapeutics had 1 more articles in the media than Janone. MarketBeat recorded 1 mentions for Lisata Therapeutics and 0 mentions for Janone. Janone's average media sentiment score of 1.89 beat Lisata Therapeutics' score of 0.96 indicating that Janone is being referred to more favorably in the news media. Company Overall Sentiment Lisata Therapeutics Positive Janone Very Positive Do institutionals and insiders believe in LSTA or ALTS? 8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 6.3% of Janone shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 4.9% of Janone shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate LSTA or ALTS? Lisata Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 495.24%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Lisata Therapeutics is more favorable than Janone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Janone 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryLisata Therapeutics beats Janone on 8 of the 13 factors compared between the two stocks. Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSTA vs. The Competition Export to ExcelMetricLisata TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.14M$6.88B$5.65B$9.04BDividend YieldN/A2.90%5.31%4.00%P/E Ratio-1.009.6390.3919.28Price / SalesN/A312.201,034.9479.82Price / CashN/A75.4646.0938.87Price / Book0.435.535.135.00Net Income-$20.84M$123.50M$113.24M$222.75M7 Day Performance-4.55%-3.32%-0.65%-0.72%1 Month Performance-31.34%-0.11%5.24%4.19%1 Year Performance-8.70%5.39%25.17%21.73% Lisata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSTALisata Therapeutics3.4306 of 5 stars$2.52+0.4%$15.00+495.2%-7.4%$21.14MN/A-1.0030Short Interest ↓ALTSJanoneN/A$6.05-8.3%N/AN/A$85.12M$39.61M0.00170Positive NewsIGMSIGM Biosciences4.8242 of 5 stars$1.43-5.3%$5.50+284.6%-92.0%$85.03M$2.92M-0.39190DBVTDBV Technologies3.8493 of 5 stars$4.13-2.5%$22.50+445.5%-53.4%$84.85M$15.73M-0.9280Analyst ForecastShort Interest ↓ADAGAdagene2.8598 of 5 stars$1.90+0.1%$8.00+320.8%-51.1%$84.16M$18.11M0.00260Short Interest ↓AVTXAvalo Therapeutics3.6935 of 5 stars$8.02-4.8%$40.00+398.8%+58.7%$83.33M$1.92M0.0040Positive NewsTNYATenaya Therapeutics3.2763 of 5 stars$1.05-0.9%$17.33+1,550.8%-84.1%$83.18MN/A-0.73110PWUPPowerUp AcquisitionN/A$10.50-18.9%N/A+14.2%$81.59MN/A0.00N/ANews CoverageGap UpALGSAligos Therapeutics4.4455 of 5 stars$22.57-12.5%$75.00+232.3%+23.6%$81.03M$15.53M-1.6990Short Interest ↓News CoverageVTGNVistagen Therapeutics1.0006 of 5 stars$2.91+0.7%N/A-46.8%$81.01M$1.06M-2.3540News CoverageZIVOZIVO BioscienceN/A$21.24+7.3%N/A+132.4%$78.80M$30,000.00-4.3510 Related Companies and Tools Related Companies Janone Competitors IGM Biosciences Competitors DBV Technologies Competitors Adagene Competitors Avalo Therapeutics Competitors Tenaya Therapeutics Competitors PowerUp Acquisition Competitors Aligos Therapeutics Competitors Vistagen Therapeutics Competitors ZIVO Bioscience Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LSTA) was last updated on 2/13/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.